Wedbush Maintains Outperform on Benitec Biopharma, Raises Price Target to $20

Benzinga · 1d ago
Wedbush analyst Yun Zhong maintains Benitec Biopharma (NASDAQ:BNTC) with a Outperform and raises the price target from $17 to $20.